Weaknesses in the UN drug control system have often been identified, related to the functioning of the key organs UNODC, INCB, and the CND; related to collaboration with the wider UN system (WHO, UNAIDS, UNDP, etc.) and related to the outdated character of several treaty provisions. What has been attempted to date to achieve more structural reform? Are existing evaluation mechanisms capable of bringing the need for reform to the table? How could a neutral and evidence-based role of UNODC as a centre of expertise be strengthened? How can these issues be related to the UN call for more ‘system-wide coherence’ and ‘delivery as one’?

A Mixture of Obvious Recommendations Deserving Support and Dubious Methods and Outcomes Requiring Scrutiny

The World Health Organization’s (WHO) Expert Committee on Drug Dependence (ECDD or Expert Committee) released in January 2019 the outcomes of the first-ever critical review of cannabis, recommending a series of changes in the current scheduling of cannabis-related substances under the UN drug control conventions. Eagerly awaited, the ECDD recommendations contain some clearly positive points, such as acknowledging the medicinal usefulness of cannabis by removing it from Schedule IV of the 1961 Single Convention on Narcotics Drugs; clarifying that cannabidiol (CBD) is not under international control; and addressing some long-standing scheduling inconsistencies.

The Chief Executives Board of the UN represents 31 UN agencies

Transform

Monday, March 11, 2019

The Chief Executives Board of the UN, representing 31 UN agencies, has adopted a common position on drug policy that endorses decriminalisation of possession and use. This comes just days before a key meeting of the Commission on Narcotic Drugs in Vienna, which will review, the UN’s 10-year Global Drug Strategy, and plan for the next one.

A civil society shadow report

International Drug Policy Consortium (IDPC)October 2018

‘Taking stock: A decade of drug policy’ evaluates the impacts of drug policies implemented across the world over the past decade, using data from the United Nations (UN), complemented with peer-reviewed academic research and grey literature reports from civil society. The important role of civil society in the design, implementation, monitoring and evaluation of global drug policies is recognised in the 2009 Political Declaration and Plan of Action on drugs, as well as in the Outcome Document of the 2016 United Nations General Assembly Special Session (UNGASS) on drugs. It is in this spirit that the International Drug Policy Consortium (IDPC) has produced this Shadow Report, to contribute constructively to high-level discussions on the next decade in global drug policy.

Post-UNGASS options for 2019/2020 – Version 4

IDPC Advocacy NoteJanuary 2018

The 2016 UNGASS on drugs was hailed as an opportunity ‘to conduct a wide-ranging and open debate that considers all options’. Although the UNGASS process had some challenges, it was nonetheless a critical moment for global drug policy reform. In June 2017, the UN Secretary General welcomed the UNGASS Outcome Document as a ‘forward-looking blueprint for action’ and called on governments to ‘honour the unanimous commitments’ made.

How the UN’s language on drugs has advanced since 1990

Diplomatic processes at the United Nations are notoriously slow and difficult, perhaps increasingly so in a modern world of multi-polar geopolitics and tensions. This is certainly no different for the highly charged and provocative issue of international drug control. After the latest high-level UN meeting on drug control – the UN General Assembly Special Session (UNGASS) on the ‘world drug problem’ in New York in April 2016 – many stakeholders came away with mixed feelings at best. Despite acknowledgements of the progress made in certain areas of the debate, and the rich content of some of the country and civil society statements, the UNGASS failed to deliver the ‘wide-ranging and open debate that considers all options’ that had been called for by the UN Secretary-General at the time, Ban Ki-Moon.

Report of the Secretary-General

UN General Assembly A/72/225July 19, 2017

This report prepared by the UN Secretary-General for the 72nd Session of the General Assembly provides an overview of the global situation on drugs, and crucially highlights cross-UN efforts to implement the UNGASS Outcome Document. In April 2017, the Secretary-General tasked UNODC with coordinating efforts across the UN system to support governments in operationalising the UNGASS Outcomes. This work should promote “efforts to achieve the Sustainable Development Goals as well as strategies to strengthen human rights-based and health-based approaches” and should further elaborate “a comprehensive organization-wide strategy across the three founding pillars of the United Nations system — development, human rights, and peace and security — in support of the preparations for the sixty-second session of the Commission, to be held in 2019” (para 20).

The commitment of the aspiring leaders to evidence-based policies must be one of the criteria taken into account

Khalid Tinasti, Ann Fordham, David R Bewley-Taylor

Thursday, May 4, 2017

The UN General Assembly Special Session on drugs held in April 2016 has been organized by the international drug control entities, but has confirmed the inclusion of other UN agencies in the global debates on drugs. Out of these, WHO and UNDP have played a major role in linking drug policy with the priorities of protecting human rights and promoting sustainable development. In May 2017, the leadership of both agencies will change. This letter reviews the aspiring leaders of these agencies’ positions on drug policies through existing literature, providing more clarity on their past or current commitment to the issue of drug policy and harm reduction stakeholders.

Post-UNGASS options for 2019/2020 – Version 2

IDPC Advocacy NoteMarch 2017

The 2016 UNGASS on drugs was hailed as an opportunity ‘to conduct a wide-ranging and open debate that considers all options’. Although the UNGASS fell short of expectations, it was nonetheless a critical moment for global drug policy reform. The next opportunity to build on progress made will be in 2019, when the 2009 Political Declaration and Plan of Action will be up for review. The document established 2019 ‘as a target date for States to eliminate or reduce significantly and measurably’ illicit drug supply and demand, the diversion and trafficking of precursors and money laundering. Evidence from the UN itself shows that these targets are unachievable.

Post-UNGASS options for 2019/2020

IDPCNovember 2016

The UN General Assembly Special Session (UNGASS) on drugs – held in New York in April 2016 – was hailed as an opportunity for the international community ‘to conduct a wide-ranging and open debate that considers all options’. Although the UNGASS was characterised by many shortcomings and disappointments, it was nonetheless a critical moment for global drug policy reform. Now that the dust has settled, one serious omission from the proces has become increasingly apparent – the fact that nothing was decided or proposed for the next important UN moment for drug policy in 2019.

A special session of the General Assembly took place in April revealing a growing divergence in the global drug policy landscape. Difficult negotiations resulted in a disappointing outcome document, perpetuating a siloed approach to drugs at the UN level. There is a clear need to realign international drug policies with the overarching 2030 Agenda and the Sustainable Development Goals, embedding the drugs issue comprehensively within the UN’s three pillars: development, human rights, and peace and security. The UNGASS process has helped to set the stage for more substantial changes in the near future, towards the next UN review in 2019.

This website

UN Drug Control

In 2011 the 1961 UN Single Convention on drugs will be in place for 50 years. In 2012 the international drug control system will exist 100 years since the International Opium Convention was signed in 1912 in The Hague. Does it still serve its purpose or is a reform of the UN Drug Conventions needed? This site provides critical background.